Actylis and Novo Nordisk Pharmatech are expanding their strategic partnership for the distribution of Benzalkonium Chloride in the United States of America.
Køge, April 22, 2026
Actylis and Novo Nordisk Pharmatech are currently partnering for the distribution of cGMP-grade Benzalkonium Chloride (BKC) to the pharmaceutical and medical device markets in Canada, Germany, Spain, Portugal, the UK, Ireland, the Nordics, Benelux and France. This successful partnership will now be extended to the United States.
By combining Novo Nordisk Pharmatech’s leading position to manufacture the highest standards of pharmaceutical grade Benzalkonium Chloride (BKC/BAK), with Actylis’ expertise and infrastructures dedicated to critical raw material distribution, we aim to provide our customers with the best end-to-end service and quality.
Statement from Actylis: “We are delighted to further expand our partnership with Novo Nordisk Pharmatech as they broaden their collaboration with us in North America. This development reflects our strong position in the United States and the shared confidence between our organizations in delivering superior quality, reliability, and service to meet the evolving needs of our customers. We look forward to building on this momentum and unlocking new opportunities together in this important market.” says Damien O’Rourke, President, Global Life Sciences at Actylis.
Statement from Novo Nordisk Pharmatech: “This expansion is a true testament to the confidence we have in Actylis. We have witnessed their solid performance and ability to service customers in Canada and across Western European countries. With their strong position in the United States, we are fully confident in their ability to continue this positive trajectory, servicing customers of the United States and ultimately helping us deliver on our purpose of enabling better medicines, enabling better lives”, says Anders Møller Koefoed, Global Head of Sales and Customer Support, Novo Nordisk Pharmatech.
About Actylis: Actylis is a global solutions provider with over 75 years of experience, specializing in streamlining the management of critical ingredients and raw materials for our business partners in pharmaceutical and biopharmaceutical industries. We offer both sourcing and manufacturing solutions tailored to meet diverse and evolving needs, ensuring a reliable, agile, and secure supply network. Our commitment to customization allows us to create flexible solutions, whether it’s a unique specification, custom packaging, or tailored logistics strategies. With deep expertise in quality and regulatory compliance, sourcing and logistics management, analytical services, and R&D support, we reduce complexities and mitigate risks, empowering our partners to focus on growing their business.
About Novo Nordisk Pharmatech: Novo Nordisk Pharmatech is a global and leading manufacturer of pharmaceutical ingredients for the pharmaceutical and biopharmaceutical industries. The company specializes in Quats (Benzalkonium Chloride) used as active pharmaceutical ingredients (APIs) and excipients in the highest available quality standard – and pharmaceutical grade Recombinant Insulin and Trypsin (TrypsiNNex®) for use in cell-based biopharmaceutical processes.
The Benzalkonium Chloride products comply with the latest pharmacopeial standards and are extensively supported by CEPs, DMFs and a comprehensive regulatory and quality assurance document package. In addition, the manufacturing site in Køge (Denmark) is audited by the Danish Medicines Agency and US FDA.
For any further question about this agreement, Contact us or Actylis.
